<DOC>
	<DOCNO>NCT00232648</DOCNO>
	<brief_summary>This study extension study SD-004-0765 , assess safety profile long-term use budesonide inhalation suspension Japanese young child bronchial asthma . Children complete study SD-004-0765 continue administration budesonide inhalation suspension judge investigator ; dose adjust appropriate within range 0.25 1.0 mg per day administer twice daily , accord symptom .</brief_summary>
	<brief_title>Long Term Safety &amp; Efficacy Budesonide Inhalation Suspension Japanese Children With Bronchial Asthma</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Budesonide</mesh_term>
	<criteria>1 . Clinical benefit continue treatment budesonide inhalation suspension expect patient bronchial asthma participate study SD0040765 , judge investigator ( ) completion study ( Visit 11 , Week 24 ) , patient 's caregiver wish continued treatment budesonide inhalation suspension A write consent participate study obtain patient 's legal representative ( person exercise parental authority patient , one applicable , guardian : principle , patient 's parent ) . 3 . The patient young 5 year old . Patients age 5 year could include study effective treatment patient 's bronchial asthma available judge investigator ( ) . 1 . Concurrent severe diseases liver , kidney , heart complication . 2 . Contraindications ( eg , know suspected allergy ) budesonide excipients contain investigational product . 3 . Other condition , investigator ( ) judge patient 's participation study inappropriate .</criteria>
	<gender>All</gender>
	<minimum_age>13 Months</minimum_age>
	<maximum_age>65 Months</maximum_age>
	<verification_date>March 2009</verification_date>
</DOC>